Eikon Therapeutics Stock

eikontx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $1.21B

Eikon Therapeutics is a drug discovery and development business focused on the movements of single proteins within cells. Eikon's proprietary microscopes can visualize the movement within these cells. Eikon Therapeutics was founded in 2019 by Luke Lavis, Robert Tjian Ph.D., Xavier Darzacq Ph.D., and Eric Betzig and is headquartered in Hayward, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Eikon Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Eikon Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Eikon Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Roger Perlmutter
President, Chief Executive Officer & Chairman
Alfred Bowie Ph.D
Chief Financial Officer
Russ Berman
Chief Technology Officer
Ashish Kheterpal
Chief Information Officer
Daniel Anderson Ph.D
Chief Scientific Officer
Benjamin Thorner JD
Chief Business Officer & General Counsel
Roy Baynes Ph.D
Chief Medical Officer & Executive Vice President

Board Members

James Tananbaum MD
Foresite Capital Management
Joshua Wolfe
Lux Capital

Frequently Asked Questions About Eikon Therapeutics’ Stock

Can you buy Eikon Therapeutics’ stock?
Eikon Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Eikon Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Eikon Therapeutics’ stock?
Yes, you can sell stock of a private company like Eikon Therapeutics. Forge can help you sell your Eikon Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Eikon Therapeutics’ stock price?
Eikon Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Eikon Therapeutics’ private market stock price with Forge Data.
What is Eikon Therapeutics’ stock ticker symbol?
Eikon Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Eikon snaps up clinical pipeline thanks to 'buyer's market,' while internal pipeline remains covert
Eikon Therapeutics emerged with the promise of Nobel Prize-winning molecule tracking technology. But now, CEO Roger Perlmutter, M.D., Ph.D., and co. are using their more than $600 million war chest for something else: buying up clinical-stage drugs.
Eikon Acquires Broad Development Pipeline, Raises $106M in Series C Funding
Led by biopharma titan Roger Perlmutter, Eikon Therapeutics kicked off 2022 with a Series B financing worth $517.8 million. The Bay Area-based biotech made another splash Thursday, announcing a $106 million Series C raise and the acquisition of exclusive, global rights to several early- to mid-stage assets.
Biotech company Eikon Therapeutics to open New York City operations base
Eikon Therapeutics, a drug discovery and development company, has signed a lease to open a New York City operations base at the Alexandria Center for Life Science at 430 E. 29th St.
Updated on: Apr 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.